You searched for Acalabrutinib - Page 4 of 26

ASH 2021: Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

September 13, 2022

Acalabrutinib plus high-frequency, low-dose subcutaneous rituximab is tolerable and effective. In addition, because it can be administered at home, it is more convenient and can decrease patient infection risk during pandemics. However, while it does control disease, it does not lead to undetectable measurable residual disease (uMRD).

ASH 2021: Dr. John Seymour on Side Effects of Acalabrutinib vs. Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

September 1, 2022

We discuss updated safety results from the ELEVATE R/R study, which is the first study comparing acalabrutinib with ibrutinib head-to-head in patients with relapsed/refractory CLL.

ASCO 2022: Acalabrutinib Versus Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): ASCEND Results at 4 Years of Follow-Up

August 25, 2022

At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, we received the four-year follow-up data update on the ASCEND trial.
This trial compared acalabrutinib (acala) to the treating doctor’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia.

AstraZeneca: Newly Approved Acalabrutinib Tablet Formulation for Patients with CLL / SLL Allows Use of Acid-Reducing Agents

August 19, 2022

The FDA has signed off on a new tablet formulation for acalabrutinib (Calquence) for patients with CLL / SLL, according to a news release from drugmaker AstraZeneca. It is now possible to take acalabrutinib along with stomach acid-reducing agents.

ASH 2021: Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

March 16, 2022

Acalabrutinib (A) and ibrutinib (I) are both highly effective Bruton tyrosine kinase (BTK) inhibitors approved for the treatment of chronic lymphocytic leukemia (CLL) and given as continuous treatments until disease progression or unacceptable toxicity.

Does acalabrutinib work in the birc3 mutation? Or is venetoclax obinutuzumab better?

January 17, 2022

Ask the Doctor Question: I have to start my first therapy soon and living in Germany. First diagnosis in 2015 and until now, watch and wait. ighv mutated, trisomie12, birc3 mutation.

Can acalabrutinib be taken in a different form – suppository, under the tongue, or some other way?

January 17, 2022

Ask the Pharmacist Question: What steps can I take to improve absorption of acalabrutinib. I had a total gastrectomy in 1974 and a Roux en Y in 2005, so my compromised

Are there any side effects of dysphasia or esophageal spasm when taking acalabrutinib?

January 12, 2022

Ask the Pharmacist Question: Are there any side effects of dysphasia or esophageal spasm when taking acalabrutinib? I began this treatment 9/1/2021 and these effects began 2-3 weeks ago. I have

ASH 2020: Dr. Davids Discusses Phase II AVO Study of Acalabrutinib + Venetoclax + Obinutuzumab for Chronic Lymphocytic Leukemia (CLL)

November 24, 2021

This video was recorded at the 62nd Annual Meeting of the American Society of Hematology, held virtually in December 2020. Dr. Davids specializes in CLL and serves on the CLL Society’s Medical Advisory Board.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: Acalabrutinib – Page 4

ASH 2021: Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

ASH 2021: Dr. John Seymour on Side Effects of Acalabrutinib vs. Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

ASCO 2022: Acalabrutinib Versus Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): ASCEND Results at 4 Years of Follow-Up

AstraZeneca: Newly Approved Acalabrutinib Tablet Formulation for Patients with CLL / SLL Allows Use of Acid-Reducing Agents

ASH 2021: Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Does acalabrutinib work in the birc3 mutation? Or is venetoclax obinutuzumab better?

Can acalabrutinib be taken in a different form – suppository, under the tongue, or some other way?

Are there any side effects of dysphasia or esophageal spasm when taking acalabrutinib?

ASH 2020: Dr. Davids Discusses Phase II AVO Study of Acalabrutinib + Venetoclax + Obinutuzumab for Chronic Lymphocytic Leukemia (CLL)

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT